BioTissue Named to Great Place to Work® and 2026 Fortune Best Workplaces in BioPharma™ for Third Consecutive Year

MIAMI, October 15, 2026 — For its third consecutive year, BioTissue has been named to the Fortune Best Workplaces in BioPharma™ list, presented by Great Place to Work^® and Fortune magazine. BioTissue ranked #21 on the 2026 list. The recognition is based on employee feedback collected through Great Place to Work^®’s independent workplace evaluation process and recognizes companies that demonstrate strong workplace cultures.

The Trust Index™ Employee Survey from Great Place to Work^® shows 87% of BioTissue Employees say it is a great place to work compared to 57% of employees at a typical U.S.-based company. It also shows that 69% of BioTissue’s employee have been with the company two or more years, with employees citing teamwork and camaraderie among the top reasons BioTissue is a great place to work — demonstrating that the culture behind the company’s success starts with the people who make it possible.

“Being featured for the third year in a row is especially meaningful because it reflects the people and culture behind everything we do,” said BioTissue President and CEO Ted Davis. “For nearly three decades, BioTissue has been driven by a shared commitment to advancing ocular health and improving the lives of patients. It starts with our people, and we’re fortunate to have a team that brings passion, collaboration and a genuine sense of purpose to our work every day.”

BioTissue’s recognition as a Great Place to Work Certified™ company demonstrates the strength of the supportive environment BioTissue has built and sustained as the company advancing its role in the ocular industry. It also speaks to the opportunity BioTissue provides for talented people to grow their careers while contributing to innovations designed to improve patient outcomes.

For career opportunities, visit https://biotissue.com/about-us/careers/.

# # #

About BioTissue Holdings, Inc.
BioTissue® is an emerging biotechnology company and leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, specializing in acute and chronic ocular surface conditions. BioTissue’s portfolio of cryopreserved amniotic membrane products are processed using its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with Investigational New Drug (IND) applications as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 1.2 million human procedures with its products and published over 440 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at www.biotissue.com/.

Media Contact
Laura DiCaprio, APR
McDougall Communications for BioTissue
[email protected] or (585)752-5805